Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315881 | 1.00 | GLA (1.00) | GLAHSD17B10KMT2AALDH1A1POLB | |
| SCHEMBL2995058 | 0.88 | GLA (0.79) | GLAHSD17B10ALDH1A1GAARAB9A | |
| SCHEMBL2995061 | 0.87 | GLA (0.77) | GLAHSD17B10ALDH1A1GAARAB9A | |
| SCHEMBL3589877 | 0.86 | GLA (0.75) | GLAHSD17B10KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3315160 | 0.86 | GLA (0.75) | GLAHSD17B10KMT2AALDH1A1POLB | |
| SCHEMBL3315157 | 0.86 | GLA (0.75) | GLAHSD17B10KMT2AALDH1A1POLB | |
| SCHEMBL3589879 | 0.86 | GLA (0.75) | GLAHSD17B10KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3319140 | 0.85 | HSD17B10 (0.74) | GLAHSD17B10ALDH1A1POLBL3MBTL1 | |
| SCHEMBL3319143 | 0.85 | HSD17B10 (0.74) | GLAHSD17B10ALDH1A1POLBL3MBTL1 | |
| SCHEMBL5909045 | 0.84 | GLA (0.72) | GLAHSD17B10KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | GLA 2225/4885HSD17B10 883/4885KMT2A 1778/4885 |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | GLA 2225/4885HSD17B10 883/4885KMT2A 1778/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | GLA 2225/4885HSD17B10 883/4885KMT2A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.